Pieter-Jan Van Dam
Overview
Explore the profile of Pieter-Jan Van Dam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Volders P, Aftimos P, Dedeurwaerdere F, Martens G, Canon J, Beniuga G, et al.
NPJ Precis Oncol
. 2025 Mar;
9(1):66.
PMID: 40065106
The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) study assessed the feasibility of using comprehensive genomic profiling (CGP) in clinical decision-making for patients with advanced cancers. This multi-center...
2.
Latacz E, Verheul S, Sillis Y, Van Dam P, Doukas M, Grunhagen D, et al.
Clin Exp Metastasis
. 2024 Dec;
42(1):1.
PMID: 39666203
The behaviour of metastases in patients with liver-metastatic colorectal cancer (CRC) is still not adequately considered during treatment planning. However, studies in large cohorts have shown that the disease course...
3.
Muilwijk T, Baekelandt L, Akand M, Daelemans S, Marien K, Waumans Y, et al.
Eur Urol Open Sci
. 2024 Jul;
66:67-74.
PMID: 39044944
Background And Objective: The tumor microenvironment (TME) in non-muscle-invasive bladder cancer (NMIBC) plays an important role in the anticancer response. We aimed to identify the prognostic biomarkers in the TME...
4.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb S, van der Heijden M, et al.
Nat Med
. 2023 Mar;
29(12):3271.
PMID: 36944799
No abstract available.
5.
Szabados B, Kockx M, Assaf Z, Van Dam P, Rodriguez-Vida A, Duran I, et al.
Eur Urol
. 2022 May;
82(2):212-222.
PMID: 35577646
Background: Neoadjuvant immunotherapies hold promise in muscle-invasive bladder cancer (MIBC). Objective: To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA)...
6.
Awada G, Jansen Y, Schwarze J, Tijtgat J, Hellinckx L, Gondry O, et al.
Cancers (Basel)
. 2021 Jan;
13(2).
PMID: 33418936
Background: Pembrolizumab improves the survival of patients with advanced melanoma. A comprehensive analysis of baseline variables that predict the benefit of pembrolizumab monotherapy has not been conducted. Methods: Survival data...
7.
Latacz E, Van Dam P, Vanhove C, Llado L, Descamps B, Ruiz N, et al.
Semin Cancer Biol
. 2020 Aug;
71:33-41.
PMID: 32735852
The histopathological growth patterns (HGPs) of liver metastases of colorectal cancer and of several other tumor types predict outcome of patients in multiple studies. The HGPs of liver metastases have...
8.
Jansen Y, Kruse V, Corthals J, Schats K, Van Dam P, Seremet T, et al.
Cancer Immunol Immunother
. 2020 Jun;
69(12):2589-2598.
PMID: 32591862
Background: Autologous monocyte-derived mRNA co-electroporated dendritic cells with mRNA encoding CD40 ligand (CD40L), CD70 and a constitutively activated TLR4 (caTLR4) (referred to as TriMixDC-MEL) have anti-tumor activity in advanced melanoma...
9.
Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb S, van der Heijden M, et al.
Nat Med
. 2020 Jun;
26(6):983.
PMID: 32555515
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
10.
Barnhill R, Van Dam P, Vermeulen P, Champenois G, Nicolas A, Rawson R, et al.
J Pathol Clin Res
. 2020 Apr;
6(3):195-206.
PMID: 32304183
Among visceral metastatic sites, cutaneous melanoma (CM) metastasises initially to the liver in ~14-20% of cases. Liver metastases in CM patients are associated with both poor prognosis and poor response...